Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 12/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027416 | 0.86 | POLB (0.56) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4023540 | 0.86 | POLB (0.56) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7358310 | 0.85 | POLB (0.60) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8252486 | 0.84 | POLB (0.54) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1157387 | 0.82 | PDE4A (0.56) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3967066 | 0.82 | POLB (0.55) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12195758 | 0.80 | POLB (0.64) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1157332 | 0.79 | PDE4A (0.58) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4204791 | 0.79 | PDE4D (0.54) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1157601 | 0.78 | MEN1 (0.58) | POLBPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524823-B2 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| EP-1846430-B1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| EP-1846430-A1 | NEW MACROLIDES | Basilea Pharmaceutica AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060264387-A1 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2006-11-23 | — | — | US | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264387-A1 | Macrolides | PPME1, MGAM, SMPD1 | POLB 2048/4885PDE4A 204/4885PDE4B 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.